Intensive chemotherapy for childhood acute lymphoblastic leukemia: Results of the randomized intercontinental trial ALL IC-BFM 2002

Journal of Clinical Oncology

Volumn 32, Issue 3, 2014, Pages 174-184

  Stary, Jan ^a   Zimmermann, Martin ^c   Campbell, Myriam ^e   Castillo, Luis ^f   Dibar, Eduardo ^g   Donska, Svetlana ^h   Gonzalez, Alejandro ⁱ   Izraeli, Shai ^j   Janic, Dragana ^l   Jazbec, Janez ^m   Konja, Josip ⁿ   Kaiserova, Emilia ^o   Kowalczyk, Jerzy ^p   Kovacs, Gabor ^q   Li, Chi Kong ^r   Magyarosy, Edina ^q   Popa, Alexander ^s   Stark, Batia ^k   Jabali, Yahia ^b   Trka, Jan ^a   Hrusak, Ondrej ^a   Riehm, Hansjörg ^c   Masera, Giuseppe ^t   Schrappe, Martin ^d   more..

^a UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^b Regional Hospital   (Czech Republic)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^e UNIVERSITY OF CHILE   (Chile)

^f Centro Hospitalario Pereira Rossell   (Uruguay)

^g HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^h Regional Oncological Center   (Ukraine)

ⁱ INSTITUTO DE HEMATOLOGÍA E INMUNOLOGÍA   (Cuba)

^j TEL AVIV UNIVERSITY   (Israel)

^k SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

^l UNIVERSITY CHILDREN S HOSPITAL   (Serbia)

^m UNIVERSITY CHILDREN S HOSPITAL   (Slovenia)

ⁿ KBC Zagreb   (Croatia)

^o University Children's Hospital   (Slovakia)

^p University of Lublin   (Poland)

^q SEMMELWEIS UNIVERSITY   (Hungary)

^r CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^s N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^t SAN GERARDO HOSPITAL   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; IFOSFAMIDE; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; TIOGUANINE; VINCRISTINE; VINDESINE; ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CHILD; CHILDHOOD CANCER; CLINICAL PROTOCOL; DRUG DOSE INCREASE; DRUG DOSE TITRATION; EVENT FREE SURVIVAL; FEMALE; GENE MUTATION; HUMAN; INFECTION; ITALY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROBABILITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHOOL CHILD; SIDE EFFECT; STOMATITIS; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; ASIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG RESISTANCE; EUROPE; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; INFANT; INTERNATIONAL COOPERATION; MORTALITY; MULTICENTER STUDY; PRESCHOOL CHILD; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RISK ASSESSMENT; RISK FACTOR; SOUTH AMERICA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIA; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; EUROPE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; INTERNATIONAL COOPERATION; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROSPECTIVE STUDIES; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; SOUTH AMERICA; TREATMENT OUTCOME;

EID: 84897018746     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.48.6522     Document Type: Article

References (45)

1. Möricke A, Zimmermann M, Reiter A, et al: Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia 24:265-284, 2010
2. Conter V, Aricò M, Basso G, et al: Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia. Leukemia 24:255-264, 2010
3. Vilmer E, Suciu S, Ferster A, et al: Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: A CLCG-EORTC report - Children Leukemia Cooperative Group. Leukemia 14:2257-2266, 2000 (Pubitemid 32042266)
4. Riehm H, Reiter A, Schrappe M, et al: Corticosteroid-dependent reduction of leukocyte count in blood as a prognostic factor in acute lymphoblastic leukemia in childhood (therapy study ALL-BFM 83) [in German]. Klin Pädiatr 199:151-160, 1987 (Pubitemid 17079852)
5. Möricke A, Reiter A, Zimmermann M, et al: Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: Treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood 111:4477-4489, 2008
6. van Dongen JJ, Seriu T, Panzer-Grümayer ER, et al: Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 352:1731-1738, 1998 (Pubitemid 28534955)
7. Cavé H, van der Werff ten Bosch J, Suciu S, et al: Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia: European Organization for Research and Treatment of Cancer - Childhood Leukemia Cooperative Group. N Engl J Med 339:591-598, 1998
8. Borowitz MJ, Devidas M, Hunger SP, et al: Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: A Children's Oncology Group study. Blood 111:5477-5485, 2008
9. Flohr T, Schrauder A, Cazzaniga G, et al: Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia 22:771-782, 2008 (Pubitemid 351552626)
10. Schrappe M, Valsecchi MG, Bartram CR, et al: Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: Results of the AIEOP-BFM-ALL 2000 study. Blood 118:2077-2084, 2011
11. Conter V, Bartram CR, Valsecchi MG, et al: Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: Results in 3184 patients on the AIEOP-BFM ALL 2000 study. Blood 115:3206-3214, 2010
12. Gaynon PS, Angiolillo AL, Carroll WL, et al: Long-term results of the Children's Cancer Group studies for childhood acute lymphoblastic leukemia 1983-2002: A Children's Oncology Group Report. Leukemia 24:285-297, 2010
13. Pieters R, Schrappe M, De Lorenzo P, et al: A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): An observational study and multicentre randomised trial. Lancet 370:240-250, 2007 (Pubitemid 47082422)
14. Bene MC, Castoldi G, Knapp W, et al: Proposals for the immunological classification of acute leukaemias: European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 9:1783-1786, 1995
15. Harrison CJ, Moorman AV, Barber KE, et al: Interphase molecular cytogenetic screening for chromosomal abnormalities of prognostic significance in childhood acute lymphoblastic leukaemia: A UK Cancer Cytogenetics Group Study. Br J Haematol 129:520-530, 2005 (Pubitemid 40769901)
16. Harrison CJ, Haas O, Harbott J, et al: Detection of prognostically relevant genetic abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: Recommendations from the Biology and Diagnosis Committee of the International Berlin-Frankfürt-Münster Study Group. Br J Haematol 151:132-142, 2010
17. Schrappe M, Reiter A, Ludwig WD, et al: Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: Results of trial ALL-BFM 90 - German-Austrian-Swiss ALL-BFM Study Group. Blood 95:3310-3322, 2000 (Pubitemid 30428458)
18. Aricò M, Valsecchi MG, Rizzari C, et al: Long-term results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: Insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster based chemotherapy. J Clin Oncol 26:283-289, 2008
19. Aricò M, Valsecchi MG, Conter V, et al: Improved outcome in high-risk childhood acute lymphoblastic leukemia defined by prednisone-poor response treated with double Berlin-Frankfurt-Muenster protocol II. Blood 100:420-426, 2002 (Pubitemid 34761102)
20. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
21. Greenwood M Jr: The natural duration of cancer: Reports on Public Health and Medical Subjects. London, United Kingdom: Her Majesty's Stationery Office 33:1-26, 1962
22. Peto R, Pike MC, Armitage P, et al: Design and analysis of randomized clinical trials requiring prolonged observation of each patient: Part I. Introduction and design. Br J Cancer 34:585-612, 1976 (Pubitemid 8004970)
23. Peto R, Pike MC, Armitage P, et al: Design and analysis of randomized clinical trials requiring prolonged observation of each patient: Part II. Analysis and examples. Br J Cancer 35:1-39, 1977 (Pubitemid 8018922)
24. Mantel N, Byar DP: Evaluation of response-time data involving transient states: An illustration using heart-transplant data. J Am Stat Assoc 69:81-86, 1974
25. Kalbfleisch JD, Prentice RL: The Statistical Analysis of Failure Time Data. New York, NY, John Wiley and Sons, 1980
26. Gray RJ: A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141-1154, 1988
27. Hunger SP, Lu X, Devidas M, et al: Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: A report from the Children's Oncology Group. J Clin Oncol 30:1663-1669, 2012
28. Möricke A, Schrauder A, Zimmermann M, et al: Major improvement of outcome in pediatric highrisk acute lymphoblastic leukemia by addition of BFM chemotherapy element "Phase IB": A comparative data analysis of trials ALL-BFM 95 and ALLBFM 2000. Blood 118, 2011 (abstr 1504)
29. Conter V, Valsecchi MG, Silvestri D, et al: Pulses of vincristine and dexamethasone in addition to intensive chemotherapy for children with intermediate-risk acute lymphoblastic leukaemia: A multicentre randomised trial. Lancet 369:123-131, 2007 (Pubitemid 46073131)
30. Matloub Y, Bostrom BC, Hunger SP, et al: Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: A report from the Children's Oncology Group. Blood 118:243-251, 2011
31. Seibel NL, Steinherz PG, Sather HN, et al: Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: A report from the Children's Oncology Group. Blood 111:2548-2555, 2008
32. Nachman JB, Sather HN, Sensel MG, et al: Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med 338:1663-1671, 1998 (Pubitemid 28267911)
33. Anderson JR, Cain KC, Gelber RD: Analysis of survival by tumor response. J Clin Oncol 1:710-719, 1983 (Pubitemid 14202071)
34. Aricò M, Schrappe M, Hunger SP, et al: Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005. J Clin Oncol 28:4755-4761, 2010
35. Schultz KR, Bowman WP, Aledo A, et al: Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: A Children's Oncology Group study. J Clin Oncol 27:5175-5181, 2009
36. Bhatia S, Landier W, Shangguan M, et al: Nonaherence to oral mercaptopurine and risk of relapse in Hispanic and non-Hispanic white children with acute lymphoblastic leukemia: A report from the Children's Oncology Group. J Clin Oncol 30:2094-2101, 2012
37. Stary J: Long-term results of national treatment trials in childhood acute lymphoblastic leukaemia in several Middle/East European countries. Memo 4:140-141, 2011
38. Micic D, Slavkovic B, Rasovic Gvozdenovic N, et al: History of treatment and long-term outcome in children with acute lymphoblastic leukaemia in Serbia. Memo 4:174-177, 2011
39. Avcin S, Prelog T, Kavcic M, et al: History of treatment and long-term outcome of childhood acute lymphoblastic leukemia in Slovenia. Memo 4:178-183, 2011
40. Derwich K, Wachowiak J, Zajac-Spychala O, et al: Long-term results in children with standard risk acute lymphoblastic leukaemia treated with 5.0 g/m2 versus 3.0 g/m2 methotrexate i.v. according to the modified ALL-BFM 90 protocol: The report of Polish Paediatric Leukemia/Lymphoma Study Group. Memo 4:184-189, 2011
41. Kaiserová E, Bubánska E, Oravkinová I, et al: Results of acute lymphoblastic leukemia treatment in children in the Slovak Republic. Memo 4:190-195, 2011
42. Stary J, Jabali Y, Trka J, et al: Long-term results of treatment of childhood acute lymphoblastic leukemia in the Czech Republic. Leukemia 24:425-428, 2010
43. Stark B, Nirel R, Avrahami G, et al: Long-term results of the Israeli National Studies in childhood acute lymphoblastic leukemia: INS 84, 89 and 98. Leukemia 24:419-424, 2010
44. Li CK, Chik KW, Ha SY, et al: Improved outcome of acute lymphoblastic leukaemia treated by delayed intensification in Hong Kong children: HKALL97 study. Hong Kong Med J 12:33-39, 2006 (Pubitemid 43287617)
45. Campbell M: Risk-adapted diagnosis and treatment of ALL in South America. Pediatr Blood Cancer 53, 2009 (abstr S.032)